Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.35 |
| ▸ | PTGIR | P43119 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493359 | 0.95 | BDKRB1 (0.36) | TRPV4CNR2BDKRB1PTGIRGSTO1 | |
| SCHEMBL492842 | 0.93 | BDKRB1 (0.36) | TRPV4CNR2BDKRB1GSTO1 | |
| SCHEMBL492558 | 0.92 | HTR7 (0.35) | TRPV4CNR2BDKRB1PTGIR | |
| SCHEMBL493506 | 0.91 | PTGIR (0.35) | BDKRB1PTGIRPSEN1PSEN2APH1B | |
| SCHEMBL492534 | 0.89 | LMNA (0.37) | TRPV4BDKRB1HPGD | |
| SCHEMBL493376 | 0.89 | ALDH1A1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL492871 | 0.89 | ALDH1A1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL492489 | 0.88 | BDKRB1 (0.37) | TRPV4CNR2BDKRB1PTGIRGSTO1 | |
| SCHEMBL493135 | 0.87 | BDKRB1 (0.39) | BDKRB1PTGIRGRM5HPGDHTT | |
| SCHEMBL493109 | 0.87 | SLC9A3 (0.35) | BDKRB1PTGIRGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | TRPV4 217/4885CNR2 24/4885BDKRB1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.